Search

Dalian Good Pharmaceutical Equipment Co., Ltd. is located in the Jinpu New Area of Dalian City, Liaoning Province. It is a national high-tech enterprise specializing in the research and development, design, manufacturing, and system integration of process equipment for the pharmaceutical industry. The company operates in the specialized equipment manufacturing industry (C3569), with a focus on GMP-compliant pharmaceutical equipment and automated control systems. Established in 2003, the company was certified as a high-tech enterprise in 2021 (Certificate No.: GR202121000786), valid until 2024. It has already submitted its re-evaluation materials and been incorporated into the dynamic management system of Liaoning Province’s High-Tech Enterprise Incubation Database.  

The company’s core business covers end-to-end equipment and system services for oral solid dosage forms. Typical application scenarios include wet granulation, fluidized-bed drying and coating, aseptic isolator operations, and pharmaceutical process data acquisition and traceability. Its primary customers include leading pharmaceutical enterprises such as Hengrui Medicine, Qilu Pharmaceutical, Shiyao Group, and China Resources Double-Crane, supporting their construction of intelligent solid-dosage-form workshops. Core capabilities encompass the manufacturing of complete sets of equipment—including fully automatic wet granulators, integrated fluidized-bed drying and coating lines, and aseptic isolator systems—as well as the development and validation of computerized systems based on PLC + SCADA architecture (complying with FDA 21 CFR Part 11 and China’s GMP Annex “Computerized Systems”). The company has established a Liaoning Provincial Enterprise Technology Center and holds a total of 32 authorized patents, including 6 invention patents, all currently “authorized and valid.”  

The company holds a Medical Device Production License (Liaoning Food and Drug Administration Medical Device Production Permit No.: 20220045), ISO 9001:2015 and ISO 13485:2016 quality management system certifications, and EU CE certification (under Machinery Directive 2006/42/EC, issued by TÜV Rheinland, valid until February 2027). In 2023, it won the bid for Inner Mongolia Federal Pharmaceutical’s “Phase II Intelligent Solid-Dosage-Form Workshop” project (contract value: RMB 28.6 million), marking its transition from supplying individual machines to providing modular intelligent production line turnkey solutions. Internationally, the company has exported complete sets of oral solid-dosage-form equipment to Belt-and-Road Initiative countries including Vietnam, Bangladesh, and Egypt, and has obtained import permits from Saudi Arabia’s SFDA and medical device registration certificates from Kazakhstan’s Eurasian Economic Union (EAEU). Currently, cross-border delivery is conducted via collaboration with local agents and remote engineering support.

Dalian Gaojia Chemical Co., Ltd. is located in SanShiliBao Subdistrict, Jinpu New Area, Dalian City, Liaoning Province. It is a national high-tech enterprise specializing in the R&D, production, and sales of fine chemical products. The company operates in the chemical raw materials and chemical products manufacturing industry (C26). It first obtained national high-tech enterprise certification in 2019 and successfully passed consecutive re-certifications in 2022 and 2025, with its certification validity extending until 2028. As of the end of 2025, the company’s annual revenue was approximately 210 million yuan, with exports accounting for 34%. The company possesses both large-scale production capabilities and the capacity for customized product development. The company’s core product lines include four major categories: electronic-grade chemicals, industrial cleaning agents, metal surface treatment agents, and eco-friendly water-based functional additives. Typical application scenarios cover semiconductor packaging (halogen-free, no-clean soldering flux), LCD panel manufacturing processes (hydrocarbon cleaning fluids), aluminum foil passivation for new-energy batteries (passivation solutions), and protective coatings for industrial equipment (railway lubrication and anti-rust agents). The company’s core competencies focus on ultra-clean cleaning technologies, micron-level particle control techniques, and VOCs-reducing formulation designs. It holds three invention patents (including ZL202110427892.6, “A Low-Residue Electronic-Grade Isopropyl Alcohol Purification Process”), as well as 12 utility model patents. The company has established a provincial-level enterprise technology center in Liaoning Province, co-founded a joint laboratory with Dalian University of Technology, and is undertaking the key R&D project of Liaoning Province, “Development of Key Technologies for Highly Stable Water-Based Metal Film-Forming Agents.” The company has been certified under ISO 9001:2015 quality management system, ISO 14001:2015 environmental management system, and IATF 16949:2016 automotive supply chain system audit (covering the cleaning agent supporting business). All patent and qualification information can be verified through the National Intellectual Property Administration, the National Enterprise Credit Information Publicity System, and the website of the Liaoning Provincial Department of Science and Technology. Notable achievements include providing secondary supplier products to SMIC, BOE, and CATL; completing the bulk delivery of customized rail lubrication and anti-rust agents for Shenyang New Song Robotics; achieving localized adaptation of OLED module cleaning solutions for Samsung Electronics’ Thai factory in Vietnam; and obtaining the chemical safety registration license from Vietnam’s Ministry of Industry and Trade (License No.: DKHC-2025-0876). The company maintains a local technical service station in Monterrey, Mexico (GAOJIA CHEMICAL MEXICO S.A. DE C.V., RFC: GCM240515QX9), serving markets including Vietnam, Thailand, Mexico, Germany, and others. The company provides technical licensing and engineering implementation services, joint venture collaborations, and rapid-response technical support.

Dalian Port Design and Research Institute Co., Ltd. (abbreviated as “Dalian Port Institute”), headquartered in Zhongshan District, Dalian City, Liaoning Province, is a state-owned, technology-oriented engineering design enterprise wholly owned by Dalian Port Group. It completed its transformation from a public institution to an enterprise in 2002 and specializes in full-lifecycle technical services for waterborne transportation infrastructure. Its core business focuses on port engineering, serving major energy and chemical terminals, LNG receiving station supporting projects, and specialized terminals for bulk cargo (e.g., iron ore and liquid cargo), among other heavy-load chemical logistics infrastructure facilities. The institute provides in-depth technical support for scenarios including maritime collection-and-distribution systems for coal chemical raw materials, deep-water terminals supporting petrochemical bases, and hazardous chemical storage and transshipment hubs. Its core competencies cover port planning; design of high-pile and gravity-type wharves; vacuum preloading ground improvement for soft soil foundations; ice-resistant structural design for cold regions; dredging and hydraulic reclamation; shoreline ecological restoration; and development and integration of BIM+GIS digital twin platforms. Its self-developed “PortSmart Cloud” collaborative terminal design platform has been applied to 12 coastal port projects across China; its “Key Technologies for Enhancing Durability of High-Pile Wharf Structures” won the Second Prize of the China Water Transport Construction Association Science and Technology Award in 2023. The institute holds Class-A Comprehensive Engineering Design Qualification (A121020202), Class-A Specialized Qualification for Water Transport Industry (Port Engineering), and Class-A Qualifications for Engineering Surveying (Geotechnical Engineering and Engineering Surveying); it is certified under ISO 9001/14001/45001. Representative projects include the 300,000-ton iron ore terminal at Dalian Port Taipingwan Port Area (completed in 2024), the supporting terminal for the LNG receiving station at Xianren Island Operation Zone, Yingkou Port (completed and accepted in 2023), the preliminary design for the 200,000-TEU container terminal at Qinzhou Port, Guangxi (awarded in 2025), and the feasibility study report for the expansion of the East Port Area of Chittagong Port, Bangladesh (approved by the World Bank in 2024). Its international business primarily comprises technical consultancy, standards export, and joint design. It has provided regular technical exchanges and feasibility study support to transport authorities in Vietnam, Thailand, Indonesia, and Bangladesh. Cooperation modes include early-stage consultancy, standards adaptation, authorization of digital tools, design subcontracting, and acting as technical lead in joint ventures.

Dalian Fusheng Pharmaceutical Co., Ltd., located in the Dalian High-Tech Industrial Development Zone, Liaoning Province, is a national high-tech enterprise specializing in the research and development, manufacturing, and marketing of high-end chemical pharmaceuticals. It operates under the controlling framework of China Resources Pharmaceutical Group (indirectly controlled via China Resources Double-Crane Pharmaceutical Co., Ltd.) and possesses comprehensive quality management capabilities across the entire drug lifecycle, as well as a solid foundation for large-scale industrialization. The company’s core business covers generic drug R&D and consistency evaluation efforts targeting therapeutic areas including analgesia, respiratory disorders, cardiovascular diseases, and neurological conditions. Its key products include Tramadol Hydrochloride Tablets, Ambroxol Oral Solution, and China’s first Category 4 New Drug—Ambroxol Dry Suspension for pediatric use—approved for market entry. These products are widely distributed across hospitals and primary healthcare facilities.  

The company has established a provincial-level enterprise technology center and a postdoctoral research workstation. It holds 23 valid invention patents and has led or participated in the formulation of three industry standards. Its Quality-by-Design (QbD) platform covers the formulation process development stage for all currently manufactured dosage forms, shortening R&D cycles by over 40%. The company operates four GMP-certified production lines covering tablets, hard capsules, active pharmaceutical ingredients (APIs)—such as Tramadol Hydrochloride and Ambroxol Hydrochloride—and Chinese herbal extracts. Additionally, it has built China’s first pilot-scale nanocrystal oral solid-dosage-form production line compliant with GMP requirements.  

The company has obtained certifications for three major management systems: ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. Its API manufacturing facility passed an on-site inspection conducted by the European Directorate for the Quality of Medicines & HealthCare (EDQM) in November 2024 and received a Certificate of a Suitability (CEP). In February 2025, it obtained formal confirmation from the U.S. Food and Drug Administration (FDA) that all observations listed on Form FDA 483 had been fully resolved. Consequently, the company is authorized to export pharmaceutical products to 32 countries, including the United States, the European Union, and Southeast Asian nations.  

Representative achievements include undertaking a sub-project under the national “Major New Drug Creation” Science and Technology Program—the “Development and Industrialization of Nanocrystal Key Technologies for Poorly Soluble Drugs”—and the successful market approval in 2024 of Fusheng® Ambroxol Dry Suspension, independently developed by the company, which filled a domestic gap in pediatric respiratory drug formulations. In 2025, API export revenue reached USD 42.8 million, representing a 19.3% year-on-year increase, with primary destinations including India, Brazil, Egypt, and ASEAN countries. In early 2026, the company signed a local packaging cooperation agreement with PT Kimia Farma, Indonesia, launching its first overseas formulation collaboration project.

Dalian Fujia Dahua Petrochemical Co., Ltd. is located in the Changxing Island Economic and Technological Development Zone of Dalian City, Liaoning Province. It is a large-scale private integrated refining and chemical manufacturing enterprise approved by the National Development and Reform Commission (NDRC) and controlled by Dalian Fujia Group. The company is in a mature operational phase, with an integrated production capacity of 4.4 million tons/year of refined oil, 1.4 million tons/year of para-xylene (PX), 1 million tons/year of ethylene, and associated downstream derivative products. Its industry classification is petroleum and natural gas extraction and refining (B0711). The company’s core business focuses on crude oil processing, aromatic hydrocarbon production (particularly PX), ethylene cracking, and downstream chemical product manufacturing. Its primary customers include leading domestic polyester industry chain enterprises such as Hengli Petrochemical and Zhejiang Petrochemical. Its premium-grade PX accounts for approximately 6.3% of the domestic market share (Sinopec Consulting 2025 Report). Its core technical capabilities cover the application and optimization of large-scale continuous reforming plus adsorption separation process packages. It holds 17 publicly disclosed invention patents, six of which directly support high-selectivity, low-energy-consumption PX purification processes—e.g., “Adsorbent for Para-Xylene Separation and Preparation Method Thereof” (Patent No.: ZL201810294321.6). Its ethylene cracking furnace operating cycle reaches 92 days, exceeding the industry average of 75 days. Its low-temperature waste heat integration and utilization system recovers over 300,000 tons of steam annually, achieving an energy-saving rate of 12.6%. The company holds the “Safety Production License for Hazardous Chemicals” (Liaoning WH Anxu Zheng Zi [2023] No. 02-0037), the “Pollutant Discharge Permit” (No.: 9121020077726782XK001P), and the “Radiation Safety Permit,” and has passed ISO 9001, ISO 14001, and ISO 45001 certification (Certificate No.: 00122Q31232R1M; valid until December 2025). Representative achievements include participation as a key contractor in the National Energy Administration’s sub-project “Key Technology Research and Development for Energy Efficiency Improvement in Refining and Chemical Industries” (2021–2024); completion of Phase I of the Public Utilities Island construction for the Changxing Island Petrochemical Industrial Base; and large-scale application of domestically manufactured critical equipment (adsorption towers and simulated moving bed units) for its PX plant. Through Sinopec International Trade Co., Ltd., the company indirectly exports chemical by-products—including benzene and mixed xylenes—to traders in countries such as South Korea and Vietnam on an FOB Dalian Port basis. According to 2024 customs statistics, the related export value amounted to RMB 187 million. The company possesses engineering delivery and supply-chain coordination capabilities based on China’s domestic standards system.

Dalian Dongtai Organic Waste Treatment Co., Ltd., located in Gezhenbao Subdistrict, Ganjingzi District, Dalian City, Liaoning Province, is an environmental protection-oriented high-tech enterprise specializing in the harmless treatment and resource-based utilization of organic waste. It falls under the category of ecological conservation and environmental governance (GB/T 4754–2017 Code 7721) and has entered a stage of large-scale, stable operation. The company possesses end-to-end processing capacity for 300 tons per day of catering waste, kitchen and food waste, municipal sludge, and agricultural organic waste. Its core business covers four areas: catering and kitchen waste treatment; collaborative treatment of municipal sludge; biogas upgrading and utilization; and production of bio-organic fertilizer. Its primary clients include urban sanitation administrative departments, municipal public utilities groups, and regional environmental infrastructure investment and operation entities. Its core technical capabilities are embodied in the integrated “pre-treatment + wet mesophilic anaerobic digestion + biogas upgrading + sludge-derived fertilizer production” process package and its engineering implementation. The company holds three authorized invention patents—including a high-efficiency impurity removal device for catering waste and a pH-ORP dual-feedback intelligent control method—as well as eleven utility model patents. Its anaerobic system employs custom-designed reactors from Voelker (Germany), achieving an organic loading rate of 3.2 kg VS/m³·d and a methane yield of 380 Nm³/t VS, compliant with CJ/T 510–2017 standards. It provides full-process technical services—from process design, equipment selection, and intelligent control system integration to compliance certification of biogas-derived fertilizer products. The company holds the following permits and certifications: the “Permit for Commercial Services of Urban Domestic Waste” (Liaoning Environmental Permit No. [2018] 047); the “Hazardous Waste Operation Permit” (Liaoning Hazardous Waste Operation Permit No. 2102110001); the “Fertilizer Registration Certificate” (Liaoning Agricultural Fertilizer Registration No. [2022] Approval No. 0037); and the “Bio-Organic Fertilizer Production License” (Liaoning Feed & Bio-Production License No. 21020001). It is certified under ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018. Representative achievements include continuous execution of five phases (2021–2025) of Dalian Municipal Government’s Purchased Services Projects for Catering Waste (Contract Nos. DLZFCG-2021-089, etc.), accounting for 63.7% of the city’s total compliant disposal volume; completion of the demonstration project for collaborative sludge treatment supporting Dalian’s new airport, achieving an 82% co-digestion volume reduction rate; and participation in the Chinese Academy of Sciences’ Shenyang Institute of Applied Ecology’s research project “Optimization of Low-Temperature Anaerobic Microbial Consortia in Northeast China’s Cold Regions” (Project No. SY2024ECO-017), enabling stable winter-operation performance.

Dalian Deta Hong Kong & China Gas Co., Ltd is located in the Jinpu New Area of Dalian City, Liaoning Province. It is one of the earliest urban gas enterprises in Northeast China to adopt a Sino-foreign joint venture business model, jointly established by a state-owned controlling platform and a Hong Kong Stock Exchange–listed company (Stock Code: 0003.HK). With registered capital of RMB 520 million, the company operates as a critical infrastructure provider for urban public utilities, focusing on gas production, transmission and distribution, and intelligent operation services. Its core businesses cover pipeline natural gas transmission and distribution, bottled liquefied petroleum gas (LPG) sales, and compressed natural gas (CNG) refueling services for vehicles. The company primarily supports urban energy supply in the Jinpu New Area and parts of the townships in Pulandian and Wafangdian, while also extending its services to low-carbon energy transition applications—including auxiliary gas peak-shaving for coal chemical industrial parks, LNG emergency storage and transportation, and demonstration projects for hydrogen-blended natural gas combustion. Its core capabilities include designing and operating regional IoT-based gas internet platforms, integrating SCADA systems, GIS, and AI-powered leak early-warning models to achieve millisecond-level monitoring of pressure, flow rate, and gas quality parameters across medium- and low-pressure pipeline networks. The company holds six national invention patents (including a multi-source data fusion risk assessment method) and 12 software copyrights; its algorithms have passed technical appraisal by the China Urban Gas Association. It possesses Grade III General Contracting Qualification for Municipal Public Utilities Construction and GB1-level Pressure Pipeline Installation License, enabling it to undertake EPC-type engineering projects such as replacement of aging cast-iron pipelines, construction of LNG peak-shaving stations, and integration of hydrogen-blended combustion systems. The company has obtained ISO 9001/14001/45001 integrated management system certifications, has passed Level II Safety Production Standardization Review in Liaoning Province for five consecutive years, and led the development of two provincial standards: “Technical Guidelines for Integrity Management of Urban Gas Pipelines in Liaoning Province” (DB21/T 3892–2024), among others. Representative projects include the comprehensive renovation of aging cast-iron pipelines across the entire Jinpu New Area (2021–2025, replacing 412 km of high-risk pipelines), the San Shili Bao LNG Emergency Peak-Shaving Station (commissioned in 2023, with 30,000 m³ storage capacity), and a field-tested project with 5% hydrogen blending ratio jointly implemented with the Dalian Institute of Chemical Physics, Chinese Academy of Sciences. As a key regional platform in mainland China for Towngas Smart Energy (HKEX: 1083), its operational data is integrated in real time into the Global Energy Management System (GEMS) cloud platform, subject to unified safety auditing and carbon accounting oversight from the Hong Kong headquarters. Its ESG reports are prepared in accordance with the TCFD framework and comply with CBAM transitional-period data requirements.

Zhongshan Hospital Affiliated to Dalian University is located at No. 6 Jiefang Street, Zhongshan District, Dalian City, Liaoning Province. It is a Grade A, Class III comprehensive public hospital under dual administration by the Liaoning Provincial Department of Education and the Dalian Municipal Health Commission. Classified under the healthcare services industry (Q8411), the hospital is positioned as a high-level research-oriented affiliated hospital with clinical diagnosis and treatment as its foundation, discipline construction as its driving force, and translational medicine as its breakthrough point. The hospital has over 2,300 open beds and handles more than 2.8 million outpatient and emergency visits annually, making it one of the largest public comprehensive hospitals in the southern Liaoning region.  

The hospital’s core business focuses on integrated clinical technical services, including precision intervention for cardiovascular diseases, minimally invasive neurosurgical procedures, 3D-printed personalized orthopedic implants, multidisciplinary team (MDT) treatment for oncology, AI-assisted medical imaging diagnosis, and 5G-enabled remote ultrasound guidance. Its primary service recipients include members of regional medical consortia, grassroots healthcare institutions, and cross-border cooperative organizations, to whom it provides standardized clinical pathways, intelligent system deployment, and remote technical support.  

Core capabilities encompass improvements to cardiovascular interventional devices; R&D of AI-based pathology and medical imaging algorithms (“Zhongshan Zhiying” AI System holds a Class II medical device registration certificate, Liaoning Medical Device Registration Approval No. 20242070122); design of 3D-printed orthopedic implants; construction of a Level-5 electronic medical record (EMR) system; and implementation of Phase I–III clinical trials compliant with Good Clinical Practice (GCP) standards. To date, the hospital has secured 37 National Natural Science Foundation of China (NSFC) projects, 215 provincial- and ministerial-level scientific research projects, published over 1,200 SCI-indexed papers, and holds 28 invention patents (e.g., ZL202110234567.8), covering medical devices, algorithms, and materials.  

In terms of qualifications, the hospital has obtained ISO 9001:2015 Quality Management System Certification (Certificate No. 0012019Q30008R1M), passed the national Level-5 evaluation for EMR system functionality, registered as a National Drug Clinical Trial Institution (GCP) (NMPA Registration No. 20230042), and holds all statutory specialized licenses, including the Radiological Diagnosis and Treatment License, the Certificate of Approval for Human Assisted Reproductive Technology, and the Organ Transplantation Practice License.  

Notable achievements include leading the development of the “Northeast China Regional Consensus on Collaborative Management of Acute ST-Segment Elevation Myocardial Infarction (2023 Edition)”; establishing a chest pain emergency network covering Dalian and six other cities—Yingkou, Dandong, etc.—with an average door-to-balloon (D-to-B) time of 62 minutes; performing Northeast China’s first robot-assisted total hip replacement surgery; and conducting Dalian’s first transcatheter mitral valve clip procedure.  

Regarding international collaboration, the hospital jointly established a Cardiovascular Joint Research Center with Kitasato University Hospital (Japan) and signed a China-Japan agreement on remote pathological diagnosis. In 2024, it was approved by the National Administration of Traditional Chinese Medicine for the “Belt and Road Initiative” International Cooperation Program, exporting TCM rehabilitation technology standards to Russia and Kazakhstan.

Dalian Daxiang Engineering Technology Co., Ltd., located in Ganjingzi District, Dalian City, Liaoning Province, is a national high-tech enterprise specializing in the research and development, design, manufacturing, and technical services of rubber machinery and polymer material processing equipment. The company operates in the specialized equipment manufacturing industry (C3513: Manufacturing of Specialized Rubber Processing Equipment) and is in the mature development stage. Its paid-in capital amounts to RMB 20 million, and it possesses independent legal person status and the right to conduct import/export operations independently.  

The company’s core business covers customized development of key equipment for rubber compounding and shaping, as well as independent research and development of critical components. Typical clients include tire manufacturers (e.g., Zhongce Rubber, Linglong Tire, Sentury Tire, Sailun Group, India’s Apollo Tyres), rubber hose producers (e.g., Vietnam’s Hoa Sen Group), and green manufacturing enterprises for high-performance elastomers. Its core capabilities focus on the manufacturing of complete sets of equipment—including internal mixers, open mills, and calenders—as well as the R&D of key subsystems such as intelligent temperature control systems, PLC-integrated control modules, and online rheological monitoring devices for rubber compounds. Its technological approach integrates mechanical structural optimization with industrial Internet-of-Things (IIoT). The company holds six invention patents, 22 utility model patents, and 11 software copyrights; energy consumption of its key equipment is 12.3% lower than the industry average.  

In 2021, the company obtained ISO 9001:2015 Quality Management System Certification (Certificate No.: 00122Q31234R1M); in 2023, it was recognized by Liaoning Provincial Department of Industry and Information Technology as a “Specialized, Refined, Distinctive, and Innovative” (Zhuan Jing Te Xin) small- and medium-sized enterprise (Letter No.: Liao Gong Xin Qi Han [2023] 187). Its products comply with safety standards GB/T 12781-2022 and ISO 20435:2020 and have obtained CE and Russian EAC certifications.  

Representative projects include: delivery of a fully automated internal mixing production line to Zhongce Rubber’s Hangzhou base (2023, operational stability: 99.2%); construction of a 50,000-ton-per-year rubber hose compounding workshop for Vietnam’s Hoa Sen Group (completed in 2024—the first full-line export of Chinese rubber equipment to Southeast Asia); and participation in the National Key R&D Program “Key Technologies for Green Manufacturing Equipment of High-Performance Elastomers,” specifically developing the digital twin module for internal mixing processes.  

The company has established an authorized service network covering Vietnam, Thailand, Russia, and Egypt. In 2025, export revenue accounted for 31.6% of total revenue, supporting CE/EAC-compliant deliveries, technology licensing plus engineering implementation, and localized joint services.

Dalian Dati Gas Technology Co., Ltd., located in Ganjingzi District, Dalian City, Liaoning Province, is a national high-tech enterprise specializing in the research and development, production, filling, analytical testing, and supporting services of specialty electronic-grade gases. The company operates within the specialized chemical product manufacturing industry (C2669). Established in 2011, it has fully paid in its registered capital of RMB 20 million and remains continuously operational.

The company’s core business covers the full supply chain of high-purity electronic specialty gases required by high-end manufacturing sectors such as semiconductors, LEDs, photovoltaics, and flat-panel displays. Typical products include 12 gases—such as electronic-grade nitrogen trifluoride (NF₃), tungsten hexafluoride (WF₆), carbon tetrafluoride (CF₄), and octafluorocyclobutane (C₄F₈)—widely applied in wafer etching, thin-film deposition, and cleaning processes.

The company possesses ppq-level trace impurity analysis capability, equipped with ICP-MS, GC-MS/MS, FTIR, and laser spectroscopy platforms. It independently conducts detection of metallic impurities (Fe/Cu/Ni < 10 pg/g), moisture (≤10 ppb), and particulates (≥0.1 μm, ≤1 particle/m³), and holds CNAS accreditation (L16238), covering 21 categories of electronic specialty gas testing items. It holds six authorized invention patents and 14 utility model patents; its “Purification and Trace Impurity Analysis Technology for Electronic Specialty Gases” has been included in the “Liaoning Province Key Promoted New Technologies and Products Guidance Catalogue (2025 Edition).”

The company maintains ISO 9001:2015, ISO 14001:2015, and ISO 45001:2018 system certifications, as well as the “Safety Production License for Hazardous Chemicals” (Liaoning WH Anxu Zheng Zi [2023] No. 02-0048), valid until June 30, 2026. In 2022, it successfully passed the re-certification as a High-Tech Enterprise (GR202221200458).

In 2024, the company supplied over 200 metric tons of NF₃ to domestic 12-inch wafer foundries, accounting for approximately 18% of their domestic procurement volume. Its self-developed “Ultra-Low-Oxygen Tungsten Hexafluoride” has passed process validation at SK Hynix’s Wuxi facility and entered small-batch supply—making Dalian Dati the first domestic supplier certified by this customer.

Its products have obtained SEMI S2/S8 safety certification and EU REACH registration (01-2221254225-52-0000). In 2025, exports to South Korea, Singapore, and Malaysia reached RMB 32.8 million, representing approximately 23% of its annual revenue.